India's Serum Joins Oxford Efforts To Expedite COVID-19 Vaccine

Marketing Pact Likely

After partnering with Merck KGaA and Cobra Biologics, Oxford University has now tied up with Serum Institute of India to manufacture its COVID-19 vaccine and a marketing pact is likely. With clinical trials of the ChAdOx1 nCoV-19 vaccine underway, Serum intends to set aside other COVID-19 vaccine development plans for the time being.

Medical_Teamwork_Covid19
Another Collaboration To Beat Coronavirus • Source: Shutterstock

The UK's University of Oxford has partnered with Serum Institute of India Ltd., the world’s largest vaccine manufacturer by volume, to produce its COVID-19 vaccine ChAdOx1 nCoV-19, as it aims to make 100 million doses of the product available by December.

While privately-owned Serum Institute declined to provide additional information, CEO Adar Poonawalla spoke about a manufacturing tie-up with the university...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip